

Conforms to Regulation (EC) No. 1907/2006 (REACH), Annex II, as amended by Commission Regulation (EU) 2020/878

SAFETY DATA SHEET

FRS-40 SEMI-GLOSS BASE BROWN LR05/8617

SECTION 1: Identification of the substance/mixture and of the company/ undertaking

1.1	Product	identifier

Product name SDS code

: FRS-40 SEMI-GLOSS BASE BROWN LR05/8617 : 40928617B

1.2 Relevant identified uses of the substance or mixture and uses advised against

Identified uses		
Paint. Professional use Industrial use		
Uses advised against		
All other uses		
Product use	: Solvent borne coating for interior use.	

1.3 Details of the supplier of the safety data sheet

MAPAERO SAS 10, Avenue de la Rijole CS30098 09103 PAMIERS Cedex France e-mail address of person : PSRA PAMIERS@akzonobel.com

responsible for this SDS

1.4 Emergency telephone number

National advisory body/Poison Center		
Telephone number	: 145	
<u>Supplier</u>		
Telephone number	: +33 (0)5 34 01 34 01	
	+33 (0)5 61 60 23 30	
Hours of operation	:	

SECTION 2: Hazards identification

2.1 Classification of the substance or mixture

Product definition : Mixture

Classification according to Regulation (EC) No. 1272/2008 [CLP/GHS]

Flam. Liq. 3, H226 Skin Irrit. 2, H315 Eye Irrit. 2, H319 STOT SE 3, H336 STOT RE 2, H373

The product is classified as hazardous according to Regulation (EC) 1272/2008 as amended.

See Section 16 for the full text of the H statements declared above.

Date of issue/Date of revision	: 1-11-2022	Version : 1.01	
Date of previous issue	: 1-10-2022	1/19	AkzoNobel

SECTION 2: Hazards identification

See Section 11 for more detailed information on health effects and symptoms.

2

2.2 Label elements

Hazard pictograms



Signal word	:	Warning
Hazard statements	:	Flammable liquid and vapor. Causes skin irritation. Causes serious eye irritation. May cause drowsiness or dizziness. May cause damage to organs through prolonged or repeated exposure.
Precautionary statements		
Prevention	:	Wear protective gloves. Wear eye or face protection. Keep away from heat, hot surfaces, sparks, open flames and other ignition sources. No smoking. Do not breathe vapor. Wash hands thoroughly after handling.
Response	:	Get medical advice or attention if you feel unwell. IF INHALED: Call a POISON CENTER or doctor if you feel unwell. Take off contaminated clothing and wash it before reuse. IF ON SKIN: Wash with plenty of water. IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. If eye irritation persists: Get medical advice or attention.
Storage	:	Store in a well-ventilated place. Keep container tightly closed. Keep cool.
Disposal		Dispose of contents and container in accordance with all local, regional, national and international regulations.
Hazardous ingredients	:	 p-butyl acetate Reaction mass of ethylbenzene and xylene 2-methoxy-1-methylethyl acetate
Supplemental label elements	:	Contains methyl methacrylate. May produce an allergic reaction. Warning! Hazardous respirable droplets may be formed when sprayed. Do not breathe spray or mist.
Annex XVII - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, mixtures and articles	:	Not applicable.
Special packaging requirem	en	<u>ts</u>
Containers to be fitted with child-resistant fastenings	:	Not applicable.
Tactile warning of danger	:	Not applicable.
2.3 Other hazards		
Product meets the criteria for PBT or vPvB according to Regulation (EC) No. 1907/2006, Annex XIII	:	This mixture does not contain any substances that are assessed to be a PBT or a vPvB.
Other hazards which do not result in classification	:	None known.



Product/ingredient name	Identifiers	%	Regulation (EC) No. 1272/2008 [CLP]	Туре
p-butyl acetate	REACH #: 01-2119485493-29 EC: 204-658-1 CAS: 123-86-4 Index: 607-025-00-1	≥10 - ≤19	Flam. Liq. 3, H226 STOT SE 3, H336 EUH066	[1] [2]
Reaction mass of ethylbenzene and xylene	REACH #: 01-2119488216-32	≥10 - <20	Flam. Liq. 3, H226 Acute Tox. 4, H312 Acute Tox. 4, H332 Skin Irrit. 2, H315 Eye Irrit. 2, H319 STOT SE 3, H335 STOT RE 2, H373 Asp. Tox. 1, H304 Aquatic Chronic 3, H412	[1] [2]
2-methoxy-1-methylethyl acetate	REACH #: 01-2119475791-29 EC: 203-603-9 CAS: 108-65-6	≤10	Flam. Liq. 3, H226 STOT SE 3, H336	[1] [2]
methyl methacrylate	REACH #: 01-2119452498-28 EC: 201-297-1 CAS: 80-62-6 Index: 607-035-00-6	≤0.3	Flam. Liq. 2, H225 Skin Irrit. 2, H315 Skin Sens. 1, H317 STOT SE 3, H335	[1] [2]
cyclohexanone	REACH #: 01-2119453616-35 CAS: 108-94-1 Index: 606-010-00-7	≤0.3	Flam. Liq. 3, H226 Acute Tox. 4, H332	[1] [2]
Hydrocarbons, C11-C14, n- alkanes, isoalkanes, cyclics, <2% aromatics	REACH #: 01-2119456620-43 EC: 926-141-6	≤0.2	Asp. Tox. 1, H304 EUH066	[1]
			See Section 16 for the full text of the H statements declared above.	

SECTION 3: Composition/information on ingredients

There are no additional ingredients present which, within the current knowledge of the supplier and in the concentrations applicable, are classified as hazardous to health or the environment, are PBTs, vPvBs or Substances of equivalent concern, or have been assigned a workplace exposure limit and hence require reporting in this section.

Type

[1] Substance classified with a health or environmental hazard

[2] Substance with a workplace exposure limit

[3] Substance meets the criteria for PBT according to Regulation (EC) No. 1907/2006, Annex XIII

[4] Substance meets the criteria for vPvB according to Regulation (EC) No. 1907/2006, Annex XIII

[5] Substance of equivalent concern

[6] Additional disclosure due to company policy

Occupational exposure limits, if available, are listed in Section 8.



SECTION 4: First aid measures

4.1 Description of first aid measures

Eye contact	:	Immediately flush eyes with plenty of water, occasionally lifting the upper and lower eyelids. Check for and remove any contact lenses. Continue to rinse for at least 10 minutes. Get medical attention.
Inhalation	:	Remove victim to fresh air and keep at rest in a position comfortable for breathing. If it is suspected that fumes are still present, the rescuer should wear an appropriate mask or self-contained breathing apparatus. If not breathing, if breathing is irregular or if respiratory arrest occurs, provide artificial respiration or oxygen by trained personnel. It may be dangerous to the person providing aid to give mouth-to-mouth resuscitation. Get medical attention. If necessary, call a poison center or physician. If unconscious, place in recovery position and get medical attention immediately. Maintain an open airway. Loosen tight clothing such as a collar, tie, belt or waistband.
Skin contact	:	Flush contaminated skin with plenty of water. Remove contaminated clothing and shoes. Continue to rinse for at least 10 minutes. Get medical attention. Wash clothing before reuse. Clean shoes thoroughly before reuse.
Ingestion	:	Wash out mouth with water. Remove dentures if any. Remove victim to fresh air and keep at rest in a position comfortable for breathing. If material has been swallowed and the exposed person is conscious, give small quantities of water to drink. Stop if the exposed person feels sick as vomiting may be dangerous. Do not induce vomiting unless directed to do so by medical personnel. If vomiting occurs, the head should be kept low so that vomit does not enter the lungs. Get medical attention. If necessary, call a poison center or physician. Never give anything by mouth to an unconscious person. If unconscious, place in recovery position and get medical attention immediately. Maintain an open airway. Loosen tight clothing such as a collar, tie, belt or waistband.
Protection of first-aiders	:	No action shall be taken involving any personal risk or without suitable training. If it is suspected that fumes are still present, the rescuer should wear an appropriate mask or self-contained breathing apparatus. It may be dangerous to the person providing aid to give mouth-to-mouth resuscitation.

4.2 Most important symptoms and effects, both acute and delayed

There are no data available on the mixture itself. The mixture has been assessed following the conventional method of the CLP Regulation (EC) No 1272/2008 and is classified for toxicological properties accordingly. See Sections 2 and 3 for details.

Exposure to component solvent vapor concentrations in excess of the stated occupational exposure limit may result in adverse health effects such as mucous membrane and respiratory system irritation and adverse effects on the kidneys, liver and central nervous system. Symptoms and signs include headache, dizziness, fatigue, muscular weakness, drowsiness and, in extreme cases, loss of consciousness.

Solvents may cause some of the above effects by absorption through the skin. Repeated or prolonged contact with the mixture may cause removal of natural fat from the skin, resulting in non-allergic contact dermatitis and absorption through the skin.

If splashed in the eyes, the liquid may cause irritation and reversible damage.

Ingestion may cause nausea, diarrhea and vomiting.

This takes into account, where known, delayed and immediate effects and also chronic effects of components from short-term and long-term exposure by oral, inhalation and dermal routes of exposure and eye contact.

Contains methyl methacrylate. May produce an allergic reaction.

Over-exposure signs/symptoms

Eye contact	: Adverse symptoms may include the following: pain or irritation watering redness
	Teuriess



SECTION 4: First aid measures

Inhalation	: Adverse symptoms may include the following: nausea or vomiting headache drowsiness/fatigue dizziness/vertigo unconsciousness
Skin contact	: Adverse symptoms may include the following: irritation redness
Ingestion	: No specific data.

4.3 Indication of any immediate medical attention and special treatment needed

Notes to physician	 Treat symptomatically. Contact poison treatment specialist immediately if large quantities have been ingested or inhaled.
Specific treatments	: No specific treatment.

SECTION 5: Firefighting measures

<u> </u>		
5.1 Extinguishing media		
Suitable extinguishing media	: Use dry chemical, CO ₂ , water spray (fog) or foam.	
Unsuitable extinguishing media	Do not use water jet.	
5.2 Special hazards arising	rom the substance or mixture	
Hazards from the substance or mixture	: Flammable liquid and vapor. Runoff to sewer may create fire or explosion hazard. In a fire or if heated, a pressure increase will occur and the container may burst, with the risk of a subsequent explosion.	
Hazardous combustion products	: Decomposition products may include the following materials: carbon dioxide carbon monoxide halogenated compounds metal oxide/oxides	
5.3 Advice for firefighters		
Special protective actions for fire-fighters	: Promptly isolate the scene by removing all persons from the vicinity of the incident if there is a fire. No action shall be taken involving any personal risk or without suitable training. Move containers from fire area if this can be done without risk. Use water spray to keep fire-exposed containers cool.	
Special protective equipment for fire-fighters	: Fire-fighters should wear appropriate protective equipment and self-contained breathing apparatus (SCBA) with a full face-piece operated in positive pressure mode. Clothing for fire-fighters (including helmets, protective boots and gloves) conforming to European standard EN 469 will provide a basic level of protection for chemical incidents.	

SECTION 6: Accidental release measures

6.1 Personal precautions, protective equipment and emergency procedures

 inadequate. Put on appropriate personal protective equipment. inadequate. Put on appropriate personal protective equipment. inadequate. Put on appropriate personal protective equipment. 		necessary and unprotected personnel from n spilled material. Shut off all ignition sources. d area. Avoid breathing vapor or mist. ppropriate respirator when ventilation is
For emergency responders	: If specialized clothing is required to de information in Section 8 on suitable ar information in "For non-emergency pe	d unsuitable materials. See also the
Date of issue/Date of revision	: 1-11-2022	Version : 1.01
Date of previous issue	: 1-10-2022	5/19 AkzoNobel

SECTION 6: Accidental release measures

6.2 Environmental precautions	: Avoid dispersal of spilled material and runoff and contact with soil, waterways, drains and sewers. Inform the relevant authorities if the product has caused environmental pollution (sewers, waterways, soil or air).
6.3 Methods and materials for	or containment and cleaning up
Small spill	: Stop leak if without risk. Move containers from spill area. Use spark-proof tools and explosion-proof equipment. Dilute with water and mop up if water-soluble. Alternatively, or if water-insoluble, absorb with an inert dry material and place in an appropriate waste disposal container. Dispose of via a licensed waste disposal contractor.
Large spill	: Stop leak if without risk. Move containers from spill area. Use spark-proof tools and explosion-proof equipment. Approach release from upwind. Prevent entry into sewers, water courses, basements or confined areas. Wash spillages into an effluent treatment plant or proceed as follows. Contain and collect spillage with non-combustible, absorbent material e.g. sand, earth, vermiculite or diatomaceous earth and place in container for disposal according to local regulations. Dispose of via a licensed waste disposal contractor. Contaminated absorbent material may pose the same hazard as the spilled product.
6.4 Reference to other sections	: See Section 1 for emergency contact information. See Section 8 for information on appropriate personal protective equipment. See Section 13 for additional waste treatment information.

SECTION 7: Handling and storage

The information in this section contains generic advice and guidance. The list of Identified Uses in Section 1 should be consulted for any available use-specific information provided in the Exposure Scenario(s).

7.1 Precautions for safe handling

Protective measures	: Put on appropriate personal protective equipment (see Section 8). Do not breathe vapor or mist. Do not ingest. Avoid contact with eyes, skin and clothing. Use only with adequate ventilation. Wear appropriate respirator when ventilation is inadequate. Do not enter storage areas and confined spaces unless adequately ventilated. Keep in the original container or an approved alternative made from a compatible material, kept tightly closed when not in use. Store and use away from heat, sparks, open flame or any other ignition source. Use explosion-proof electrical (ventilating, lighting and material handling) equipment. Use only non-sparking tools. Take precautionary measures against electrostatic discharges. Empty containers retain product residue and can be hazardous. Do not reuse container.
Advice on general occupational hygiene	: Eating, drinking and smoking should be prohibited in areas where this material is handled, stored and processed. Workers should wash hands and face before eating, drinking and smoking. Remove contaminated clothing and protective equipment before entering eating areas. See also Section 8 for additional information on hygiene measures.

7.2 Conditions for safe storage, including any incompatibilities

Store in accordance with local regulations. Store in a segregated and approved area. Store in original container protected from direct sunlight in a dry, cool and well-ventilated area, away from incompatible materials (see Section 10) and food and drink. Store locked up. Eliminate all ignition sources. Separate from oxidizing materials. Keep container tightly closed and sealed until ready for use. Containers that have been opened must be carefully resealed and kept upright to prevent leakage. Do not store in unlabeled containers. Use appropriate containment to avoid environmental contamination. See Section 10 for incompatible materials before handling or use.

Seveso Directive - Reporting thresholds

Danger criteria

Date of issue/Date of revision	: 1-11-2022	Version : 1.01	
Date of previous issue	: 1-10-2022	6/19	AkzoNobel

S	SECTION 7: Handling and storage				
		Notification and MAPP threshold	Safety report threshold		
	P5c	5000 tonne	50000 tonne		

7.3 Specific end use(s)

Recommendations	: Not available.
Industrial sector specific solutions	: Not available.

SECTION 8: Exposure controls/personal protection

The information in this section contains generic advice and guidance. Information is provided based on typical anticipated uses of the product. Additional measures might be required for bulk handling or other uses that could significantly increase worker exposure or environmental releases.

8.1 Control parameters

Occupational exposure limits

Product/ingredient nam	e Exposure limit values
<mark>p</mark> -butyl acetate	SUVA (Switzerland, 1/2020). Notes: not temporary STEL: 960 mg/m ³ 15 minutes. STEL: 200 ppm 15 minutes. TWA: 480 mg/m ³ 8 hours. TWA: 100 ppm 8 hours.
Reaction mass of ethylbenzene and	
2-methoxy-1-methylethyl acetate	SUVA (Switzerland, 1/2018). TWA: 50 ppm 8 hours. TWA: 275 mg/m ³ 8 hours. STEL: 50 ppm 15 minutes. STEL: 275 mg/m ³ 15 minutes.
methyl methacrylate	SUVA (Switzerland, 1/2020). Skin sensitizer. Notes: not temporary STEL: 420 mg/m ³ 15 minutes. STEL: 100 ppm 15 minutes. TWA: 210 mg/m ³ 8 hours. TWA: 50 ppm 8 hours.
cyclohexanone	SUVA (Switzerland, 1/2020). Absorbed through skin. Notes: not temporary STEL: 200 mg/m ³ 15 minutes. STEL: 50 ppm 15 minutes. TWA: 100 mg/m ³ 8 hours. TWA: 25 ppm 8 hours.
procedures atm of t pro the the limi atm of e (We	is product contains ingredients with exposure limits, personal, workplace hosphere or biological monitoring may be required to determine the effectiveness he ventilation or other control measures and/or the necessity to use respiratory tective equipment. Reference should be made to monitoring standards, such as following: European Standard EN 689 (Workplace atmospheres - Guidance for assessment of exposure by inhalation to chemical agents for comparison with t values and measurement strategy) European Standard EN 14042 (Workplace cospheres - Guide for the application and use of procedures for the assessment exposure to chemical and biological agents) European Standard EN 482 orkplace atmospheres - General requirements for the performance of procedures the measurement of chemical agents) Reference to national guidance
Date of issue/Date of revision : 1-	11-2022 Version : 1.01
Date of previous issue : 1-	10-2022 7/19 AkzoNobel

SECTION 8: Exposure controls/personal protection

documents for methods for the determination of hazardous substances will also be required.

DNELs/DMELs

NormalNormal DNELLong term Dermal DWdayBwday Seneral populationSeneral populationSDNELLong term Dermal Inhalation12 mg/m2 PopulationGeneral populationSDNELLong term Inhalation12 mg/m2 InhalationGeneral populationSDNELLong term Inhalation48 mg/m2WorkersSDNELLong term Inhalation102.34 mg/ populationGeneral populationLDNELLong term Inhalation48 mg/m2General populationLDNELShort term Inhalation659.7 mg/ populationGeneral populationSDNELShort term Inhalation859.7 mg/ populationGeneral populationSDNELShort term Inhalation960 mg/m3WorkersLDNELShort term Inhalation960 mg/m3WorkersSDNELLong term Inhalation1.6 mg/kg populationGeneral populationSDNELLong term Inhalation1.6 mg/kg populationGeneral populationSDNELLong term Inhalation1.6 mg/kg populationGeneral populationSDNELLong term Inhalation1.6 mg/kg populationGeneral populationSDNELLong term Inhalation1.6 mg/kg populationGeneral populationSDNELLong term Inhalation1.6 mg/kg populationGeneral populationSDNELLong term 	Effects	Population	Value	Exposure	Туре	Product/ingredient name
DNELLong term Dermal3.4 mg/mgGeneralS.DNELLong term Dermal7 mg/kgWorkersS.DNELLong term12 mg/m³GeneralS.DNELLong term12 mg/m³GeneralS.DNELLong term102.34 mg/GeneralL.DNELLong term102.34 mg/GeneralL.DNELLong term148 mg/m³WorkersL.DNELLong term480 mg/m³WorkersL.DNELLong term480 mg/m³WorkersL.DNELLong term480 mg/m³WorkersL.DNELShort term859.7 mg/GeneralL.Inhalationm³populationS.DNELShort term960 mg/m³WorkersS.DNELShort term960 mg/m³WorkersS.DNELLong term1.6 mg/kgGeneralS.populationDNELLong term Dermal1.6 mg/kgGeneralS.populationDNELLong term Dermal180 mg/kgGeneralS.populationDNELLong term Dermal180 mg/kgGeneralS.populationDNELLong term Dermal180 mg/kgGeneralS.populationDNELLong term Dermal180 mg/kgWorkersS.populationDNELLong term Dermal180 mg/kgWorkersS.populationDNELLong term Dermal180 mg/kgWorkers <td< td=""><td>Systemic</td><td></td><td></td><td>Long term Oral</td><td>DNEL</td><td>n-butyl acetate</td></td<>	Systemic			Long term Oral	DNEL	n-butyl acetate
NetLong term Dermal bw/daybw/day WorkersSDNELLong term12 mg/m² bw/dayGeneral generalSDNELLong term148 mg/m²WorkersSInhalationInhalationm²General populationLDNELLong term102.34 mg/ populationGeneral populationLDNELLong term102.34 mg/ populationGeneral populationLDNELLong term162.34 mg/ populationGeneral populationLDNELShort term859.7 mg/ populationGeneral populationLDNELShort term960 mg/m²WorkersLInhalationm² inhalationBS9.7 mg/ populationGeneral populationLDNELShort term960 mg/m²WorkersSInhalationInhalation inhalationInhalation populationSDNELLong term1.6 mg/kg bw/dayGeneral populationSDNELLong term108 mg/kg bw/dayGeneral populationSDNELLong term108 mg/kg bw/dayGeneral populationSDNELLong term108 mg/kg bw/dayGeneral populationSDNELLong term108 mg/kg bw/dayGeneral populationSDNELLong term108 mg/kg bw/dayGeneral populationSDNELLong term104 mg/m² gopulationGeneral populationSDNEL						
DNELLong term Dermal7 mg/kg bw/dayWorkersS populationDNELLong term12 mg/m² inhalationGeneral populationS populationS populationDNELLong term102.34 mg/ inhalationGeneral populationLong populationLong inhalationI m²DNELLong term480 mg/m² inhalationGeneral populationLong inhalationLong inhalationLong inhalationMorkersLong inhalationDNELShort term859.7 mg/ inhalationGeneral m² populationS populationS populationS populationDNELShort term960 mg/m² inhalationWorkersL inhalationS populationS populationS populationDNELShort term960 mg/m² inhalationWorkersS inhalationS populationS populationS populationDNELLong term Oral1.6 mg/kg bw/dayGeneral populationS populationS populationS populationDNELLong term Dermal inhalation108 mg/kg bw/dayGeneral populationS populationS populationDNELLong term Dermal inhalation108 mg/kg bw/dayGeneral populationS populationS populationDNELLong term Dermal inhalation108 mg/kg bw/dayGeneral populationS populationS populationDNELLong term Dermal inhalation104 mg/m² populationGen	Systemic			Long term Dermal	DNEL	
methyl methacrylate DNEL Long term 12 mg/m ³ General population S DNEL Long term 48 mg/m ³ Workers S DNEL Long term 48 mg/m ³ Workers L DNEL Long term 102.34 mg/ General population L DNEL Long term 480 mg/m ³ Workers L Inhalation m ³ Workers L Inhalation m ³ population DNEL Short term 859.7 mg/ General population population D DNEL Short term 960 mg/m ³ Workers L Inhalation m ³ population D DNEL Short term 960 mg/m ³ Workers S Inhalation D			,			
DNEL Inhalation Inhalation12 mg/m³ opulation populationGeneral populationSDNEL Inhalation Inhalation00.2.34 mg/m³ WorkersGeneral populationLDNEL Inhalation102.34 mg/m³ WorkersGeneral populationLDNEL Inhalation102.34 mg/m³ WorkersGeneral populationLDNEL InhalationSb9.7 mg/ BopulationGeneral populationLDNEL InhalationShort term Inhalation859.7 mg/ BopulationGeneral populationLDNEL InhalationShort term Inhalation860 mg/m³ WorkersWorkersLDNEL InhalationShort term Inhalation960 mg/m³ WorkersWorkersLDNEL InhalationDNEL InhalationI.6 mg/kg BopulationGeneral populationSDNEL InhalationDNEL InhalationI.6 mg/kg BopulationGeneral SSDNEL InhalationDNEL InhalationI.6 mg/kg BopulationGeneral SSDNEL InhalationDNEL InhalationCaneral Bow/daySDNEL InhalationDNEL InhalationSWorkersSDNEL InhalationDNEL InhalationSGeneral Bow/daySDNEL InhalationDNEL InhalationSGeneral Bow/daySDNEL InhalationDNEL InhalationSGeneral Bow/daySDNEL InhalationDNEL InhalationCaneral Bow/dayS	Systemic	Workers		Long term Dermal	DNEL	
Inhalation DNEL Long termpopulation 48 mg/m³population Workerspopulation S S InhalationDNEL InhalationLong term102.34 mg/ opoulationGeneral populationL InhalationDNEL InhalationLong term480 mg/m³WorkersL InhalationDNEL InhalationDNEL InhalationS9.7 mg/ GeneralGeneral populationL InhalationDNEL InhalationShort term859.7 mg/ GeneralGeneral populationL InhalationDNEL InhalationShort term960 mg/m³ WorkersWorkersL InhalationDNEL InhalationShort term960 mg/m³ WorkersWorkersS InhalationDNEL InhalationDNEL Inhalation1.6 mg/kg populationGeneral populationS populationDNEL InhalationDNEL InhalationIng general populationS populationS populationS populationDNEL InhalationDNEL InhalationIng general populationS populationS populationS populationDNEL InhalationDNEL InhalationIng general populationS populationS populationS populationDNEL InhalationDNEL InhalationIng general populationS populationS populationS populationDNEL InhalationDNEL InhalationIng general populationS populationS populationS populationDNEL InhalationDNEL <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>						
DNEL Inhalation InhalationLong term inhalation48 mg/m³WorkersSDNEL 	Systemic		12 mg/m³		DNEL	
Inhalation Inhalation00DNEL InhalationLong term Inhalation102.34 mg/ populationGeneral populationLong termDNEL InhalationNet InhalationSbo.7 mg/ m³General GeneralLong termDNEL InhalationSbo.7 term m³859.7 mg/ WorkersGeneral GeneralLong termDNEL InhalationSbort term Inhalation859.7 mg/ WorkersGeneral WorkersLong General populationDNEL InhalationDNEL InhalationSbort term Boom g/m³WorkersLong General populationDNEL InhalationDNEL InhalationLong term DNEL Inhalation1.6 mg/kg Boreral populationSongeral Songeral Songeral WorkersS Songeral Songeral WorkersS Songeral Songeral WorkersS Songeral Songeral Songeral WorkersS Songeral Songeral Songeral WorkersS Songeral Songeral Songeral WorkersS Songeral Songeral Songeral Songeral Songeral Songeral WorkersS Songeral <br< td=""><td></td><td></td><td></td><td></td><td></td><td></td></br<>						
DNELLong term Inhalation102.34 mg/ m³General populationLi populationDNELLong term Inhalation480 mg/m³WorkersLi populationLi populationLi populationDNELShort term Inhalation859.7 mg/ m³General populationLi populationLi populationLi populationDNELShort term Inhalation960 mg/m³WorkersLi populationLi populationLi populationDNELShort term Inhalation960 mg/m³WorkersSDNELShort term Inhalation960 mg/m³WorkersSDNELShort term Inhalation960 mg/m³WorkersSDNELLong term Oral Inhalation1.6 mg/kg bw/dayGeneral populationSDNELLong term Oral Inhalation1.6 mg/kg bw/dayGeneral populationSDNELLong term Dermal Inhalation108 mg/kg bw/dayGeneral populationSDNELLong term Dermal Inhalation108 mg/kg bw/dayGeneral populationSmethyl methacrylateDNELLong term Dermal Inhalation828 mg/m³WorkersSDNELLong term Dermal Inhalation208 mg/m³WorkersSDNELLong term Dermal Inhalation208 mg/m³WorkersSDNELLong term Dermal Inhalation208 mg/m³WorkersSDNELLong term Dermal Inhalation108 mg/kg bw/dayGeneral <b< td=""><td>Systemic</td><td>Workers</td><td>48 mg/m³</td><td></td><td>DNEL</td><td></td></b<>	Systemic	Workers	48 mg/m³		DNEL	
Inhalationm³populationDNELLong term480 mg/m³WorkersLiInhalation859.7 mg/ populationGeneral GeneralLiDNELShort term859.7 mg/ populationGeneral GeneralSDNELShort term960 mg/m³WorkersLiInhalationm³m9WorkersLiInhalationm3WorkersLiDNELShort term960 mg/m³WorkersSInhalation1.6 mg/kgBeneral populationSDNELLong term1.4 mg/m³General populationSpopulationDNELLong term1.7 mg/m³General populationSDNELLong term1.8 mg/m³General populationSDNELLong term Dermal108 mg/kg bw/dayBoreral populationSDNELLong term Dermal108 mg/kg bw/dayWorkersSDNELLong term Dermal108 mg/kg bw/dayWorkersSDNELLong term Dermal180 mg/kg bw/dayWorkersSDNELLong term289 mg/m³WorkersSInhalationDNELLong term1.4 mg/m³General populationSDNELLong term104 mg/m³General populationSDNELLong term289 mg/m³WorkersSInhalationDNELLong term104 mg/m³General populationLiDNELLong term						
DNEL InhalationLong term Inhalation480 mg/m³WorkersLink General populationDNEL InhalationDNEL Short term859.7 mg/ BS0.7 mg/ General populationGeneral populationLinkalationDNEL InhalationShort term960 mg/m³WorkersLinkalationDNEL InhalationShort term960 mg/m³WorkersSDNEL InhalationDNEL InhalationShort term960 mg/m³WorkersSDNEL InhalationDNEL InhalationLong term1.6 mg/kg Bw/dayGeneral populationSDNEL Long termDNEL InhalationLong term77 mg/m³WorkersSDNEL Long termDNEL InhalationDNEL Bw/dayGeneral populationSDNEL InhalationDNEL InhalationDNEL Bw/dayGeneral WorkersSDNEL InhalationDNEL InhalationSWorkersSDNEL InhalationShort term Inhalation289 mg/m³WorkersSDNEL InhalationDNEL DNEL InhalationSGeneral SSDNEL InhalationDNEL InhalationSGeneral SSDNEL InhalationDNEL DNEL InhalationSGeneral SSDNEL InhalationDNEL InhalationSGeneral SSDNEL InhalationDNEL InhalationSGeneral SSDNEL InhalationDNEL InhalationSGene	Local				DNEL	
InhalationoDNELShort term859.7 mg/ populationGeneral populationDNELShort term859.7 mg/ populationGeneral populationSDNELShort term960 mg/m³WorkersLi inhalationDNELShort term960 mg/m³WorkersSInhalationDNELShort term960 mg/m³WorkersSInhalationDNELShort term960 mg/m³General populationSDNELLong term1.6 mg/kgGeneral populationSDNELLong term1.6 mg/kgGeneral populationSDNELLong term77 mg/m³WorkersSDNELLong term Dermal108 mg/kgGeneral populationSDNELLong term Dermal180 mg/kgWorkersSDNELShort term289 mg/m³WorkersSDNELShort term289 mg/m³WorkersSDNELLong term Dermal1.6 mg/kgGeneral populationSDNELLong term Dermal8.2 mg/kgGeneral populationSDNELLong term Dermal1.6 mg/kgGeneral populationSDNELLong term Dermal1.6 mg/kgGeneral populationSDNELLong term Dermal1.04 mg/m³General populationSDNELLong term Dermal1.04 mg/m³General generalSDNELLong term Dermal1 mg/kgGeneral general <t< td=""><td></td><td></td><td></td><td></td><td></td><td></td></t<>						
DNEL InhalationShort term m³859.7 mg/ opulationGeneral populationLi inhalationDNEL InhalationDNEL Short termShort term 960 mg/m³WorkersLi inhalationDNEL InhalationShort term960 mg/m³WorkersLi inhalationDNEL InhalationShort term960 mg/m³WorkersSDNEL InhalationDNEL InhalationLong term1.6 mg/kg populationGeneral populationSDNEL InhalationLong term1.6 mg/kg populationGeneral populationSDNEL InhalationLong term77 mg/m³WorkersSDNEL InhalationLong term108 mg/kg bw/dayGeneral populationSDNEL InhalationDNEL InhalationInma/kg bw/dayGeneral populationSDNEL InhalationDNEL InhalationLong term180 mg/kg bw/dayGeneral populationSDNEL InhalationDNEL InhalationCong term289 mg/m³WorkersSDNEL InhalationDNEL InhalationLong term13.67 mg/ gopulationSDNEL InhalationDNEL InhalationCong term208 mg/m³WorkersSDNEL InhalationDNEL InhalationCong term208 mg/m³WorkersSDNEL InhalationDNEL InhalationCong term208 mg/m³WorkersSDNEL InhalationDNEL InhalationCong term208 mg/m³W	Local	Workers	480 mg/m³		DNEL	
Inhalationm³population GeneralDNELShort term859.7 rg/ InhalationGeneralSDNELShort term960 mg/m³WorkersLInhalationDNELShort term960 mg/m³WorkersSDNELShort term960 mg/m³WorkersSInhalationDNELLong term Oral1.6 mg/kgGeneralSDNELLong term14.8 mg/m³GeneralSDNELLong term77 mg/m³WorkersSInhalationDNELLong term108 mg/kgGeneralSDNELLong term Dermal108 mg/kgGeneralSInhalationDNELLong term Dermal108 mg/kgGeneralSDNELShort term289 mg/m³WorkersSInhalationDNELLong term Dermal8.2 mg/kgGeneralSDNELShort term289 mg/m³WorkersSInhalationDNELLong term Dermal8.2 mg/kgGeneralSDNELLong term Dermal8.2 mg/kgGeneralSInhalationDNELLong term14.3 mg/m³GeneralSDNELLong term104 mg/m³GeneralSInhalationDNELLong term208 mg/m³WorkersSInhalationDNELLong term208 mg/m³WorkersSInhalationDNELLong term104 mg/kgGeneralSDNELLong term<						
DNEL InhalationShort term m³859.7 mg/ populationGeneral populationSReaction mass of ethylbenzene and xyleneDNEL DNELShort term Inhalation960 mg/m³WorkersLDNEL InhalationDNEL DNELCong term Inhalation1.6 mg/kg populationGeneral populationSDNEL Long termLong term Inhalation1.6 mg/kg populationGeneral populationSDNEL InhalationDNEL InhalationLong term Inhalation1.8 mg/m³ PopulationGeneral populationSDNEL InhalationDNEL InhalationLong term Dermal Inhalation108 mg/kg PopulationGeneral populationSDNEL InhalationDNEL InhalationLong term Dermal Inhalation108 mg/kg PopulationGeneral populationSmethyl methacrylateDNEL InhalationLong term Dermal Inhalation8.2 mg/m³ PopulationWorkersSmethyl methacrylateDNEL Iong term Dermal InhalationS.2 mg/kg PopulationGeneral populationSDNEL Iong term InhalationDNEL Iong term Inhalation208 mg/m³ PopulationWorkersSDNEL Iong term InhalationDNEL Iong term208 mg/m³ PopulationWorkersSDNEL Iong term InhalationDNEL Iong term208 mg/m³ PopulationWorkersSDNEL Iong term InhalationDNEL Iong term208 mg/m³ PopulationWorkersSDNEL<	Local				DNEL	
Reaction mass of ethylbenzene and xyleneInhalation DNELm³ Short term Inhalationpopulation WorkersLi InhalationDNELShort term Inhalation960 mg/m³WorkersSDNELShort term Inhalation1.6 mg/kg bw/dayGeneral populationSDNELLong term Oral1.6 mg/kg bw/dayGeneral populationSDNELLong term Inhalation77 mg/m³WorkersSDNELLong term Inhalation77 mg/m³WorkersSDNELLong term Dermal Inhalation108 mg/kg bw/dayGeneral populationSDNELShort term Inhalation289 mg/m³WorkersSDNELShort term Inhalation289 mg/m³WorkersSDNELShort term Inhalation289 mg/m³WorkersSDNELLong term Dermal Inhalation8.2 mg/kg bw/dayGeneral populationSDNELLong term Dermal Inhalation1.6 mg/kg bw/dayGeneral populationSDNELLong term Inhalation1.6 mg/kg bw/dayGeneral populationSDNELLong term Inhalation208 mg/m³WorkersSDNELLong term Inhalation208 mg/m³WorkersSDNELLong term Inhalation208 mg/m³WorkersSDNELLong term Inhalation208 mg/m³WorkersSDNELLong term Inhalation1.5 mg/kg BoreralS<						
DNEL Inhalation DNELShort term Inhalation DNEL960 mg/m³ WorkersWorkersLi MorkersReaction mass of ethylbenzene and xyleneDNEL DNELLong term Oral Inhalation1.6 mg/kg bw/dayGeneral populationS populationDNEL InhalationLong term Oral Inhalation1.6 mg/kg Bow/dayGeneral populationS populationDNEL InhalationLong term Dermal Inhalation108 mg/kg bw/dayGeneral populationS populationDNEL InhalationLong term Dermal Inhalation108 mg/kg bw/dayGeneral populationS populationDNEL InhalationLong term Dermal Inhalation108 mg/kg bw/dayGeneral populationS populationDNEL InhalationLong term Dermal Inhalation108 mg/kg bw/dayWorkersS populationDNEL InhalationDNEL InhalationLong term Dermal Inhalation8.2 mg/kg bw/dayGeneral populationS populationDNEL InhalationDNEL InhalationLong term Inhalation104 mg/m³ GeneralGeneral populationS populationDNEL InhalationDNEL InhalationLong term Inhalation208 mg/m³ WorkersWorkersS InhalationDNEL InhalationDNEL InhalationLong term Inhalation208 mg/m³ WorkersWorkersS InhalationDNEL InhalationDNEL InhalationLong term Inhalation104 mg/m³ GeneralGeneral CeneralS Inhala	Systemic	-			DNEL	
Reaction mass of ethylbenzene and xyleneDNELInhalation Short term Long term Oral960 mg/m³ UWrkersWorkersSReaction mass of ethylbenzene and xyleneDNELLong term Oral1.6 mg/kg bw/dayGeneral populationSDNELLong term Inhalation DNELLong term DNEL14.8 mg/m³ populationGeneral populationSDNELLong term Inhalation DNELLong term Dermal Inhalation108 mg/kg bw/dayGeneral populationSDNELLong term Dermal Inhalation108 mg/kg bw/dayGeneral populationSDNELLong term Dermal Inhalation108 mg/kg bw/dayWorkersSDNELShort term Inhalation289 mg/m³ bw/dayWorkersSDNELShort term Inhalation289 mg/m³ bw/dayWorkersSDNELLong term Dermal Inhalation8.2 mg/kg bw/dayGeneral populationSDNELLong term Dermal Inhalation13.67 mg/ WorkersSGeneral populationSDNELLong term Inhalation74.3 mg/m³ General populationGeneral populationLong termScyclohexanoneDNELLong term Inhalation208 mg/m³ WorkersWorkersSDNELLong term Inhalation1 mg/kg BowldayGeneral gopulationSDNELLong term Inhalation1 mg/kg BowldayGeneral GeneralSDNELLong term Inhalation1 mg						
DNELShort term Inhalation960 mg/m³WorkersSReaction mass of ethylbenzene and xyleneDNELLong term Oral1.6 mg/kg bw/dayGeneral populationSDNELLong term Inhalation14.8 mg/m³General populationSDNELLong term Inhalation77 mg/m³WorkersSDNELLong term Inhalation108 mg/kg bw/dayGeneral populationSDNELLong term Dermal Inhalation108 mg/kg bw/dayGeneral populationSDNELLong term Dermal Inhalation108 mg/kg bw/dayGeneral populationSDNELLong term Dermal Inhalation180 mg/kg bw/dayGeneral populationSDNELShort term Inhalation289 mg/m³ bw/dayWorkersSDNELLong term Dermal Inhalation13.67 mg/ bw/dayWorkersSDNELLong term Dermal Inhalation104 mg/m³ general populationGeneral populationLong populationLong populationDNELLong term Inhalation104 mg/m³ general populationGeneral populationLong populationLong general populationSDNELLong term Inhalation208 mg/m³ gopulationWorkersSDNELLong term Inhalation208 mg/m³ gopulationWorkersSDNELLong term Inhalation1 mg/kg general gopulationGeneral gopulationSDNELLong term Dermal<	Local	Workers	960 mg/m³		DNEL	
Reaction mass of ethylbenzene and xyleneInhalation						
Reaction mass of ethylbenzene and xyleneDNEL DNELLong term Oral Inhalation1.6 mg/kg bw/dayGeneral populationSDNEL InhalationLong term Inhalation14.8 mg/m³ OpulationGeneral populationSDNEL InhalationLong term Inhalation77 mg/m³WorkersSDNEL InhalationLong term Dermal Bw/day108 mg/kg Bw/dayGeneral populationSDNEL InhalationLong term Dermal Inhalation108 mg/kg Bw/dayGeneral populationSDNEL InhalationLong term Dermal Inhalation108 mg/kg Bw/dayGeneral populationSDNEL InhalationDNEL InhalationSSSDNEL InhalationDNEL InhalationLong term Dermal B.2 mg/m³WorkersSMethyl methacrylateDNEL InhalationLong term Inhalation13.67 mg/ Beneral populationGeneral populationSDNEL InhalationLong term Inhalation104 mg/m³ Beneral populationGeneral populationSDNEL InhalationLong term Inhalation104 mg/m³ Beneral populationSDNEL InhalationLong term Inhalation208 mg/m³ Beneral BopulationSDNEL InhalationLong term Inhalation104 mg/m³ Beneral BopulationSDNEL InhalationDNEL Inhalation108 mg/m³ Beneral BopulationSDNEL InhalationLong term Dermal Inhalation1 mg/kg Bene	Systemic	Workers	960 mg/m³		DNEL	
xylenebw/daypopulationDNELLong term14.8 mg/m³General populationSDNELLong term77 mg/m³WorkersSInhalationDNELLong term Dermal108 mg/kg bw/dayGeneral populationSDNELLong term Dermal108 mg/kg bw/dayGeneral populationSDNELLong term Dermal108 mg/kg bw/dayWorkersSDNELLong term Dermal180 mg/kg bw/dayWorkersSDNELShort term Inhalation289 mg/m³ bw/dayWorkersSDNELShort term Inhalation289 mg/m³ bw/dayWorkersSDNELLong term Dermal8.2 mg/kg bw/dayGeneral populationSDNELLong term Dermal13.67 mg/ kg bw/dayGeneral populationSDNELLong term Inhalation104 mg/m³ General populationSDNELLong term Inhalation208 mg/m³ WorkersWorkersSDNELLong term Inhalation208 mg/m³ WorkersSDNELLong term Inhalation208 mg/m³ WorkersSDNELLong term Inhalation1 mg/kg Beneral populationSDNELShort term Dermal1 mg/kg BordayGeneral SSDNELShort term Oral1 mg/kg Bw/dayGeneral SSDNELLong term Oral1 mg/kg Bw/dayGeneral SSDNELLong term Oral1						
DNELLong term Inhalation14.8 mg/m³ populationGeneral populationSDNELLong term Inhalation77 mg/m³WorkersSDNELLong term Dermal108 mg/kg bw/dayGeneral populationSDNELLong term Dermal180 mg/kg bw/dayWorkersSDNELLong term Dermal180 mg/kg bw/dayWorkersSDNELShort term Inhalation289 mg/m³WorkersLDNELShort term Inhalation289 mg/m³WorkersSDNELLong term Dermal8.2 mg/kg bw/dayGeneral opulationSDNELLong term Dermal13.67 mg/ WorkersWorkersSDNELLong term Dermal13.67 mg/ WorkersSDNELLong term Inhalation104 mg/m³General populationSDNELLong term Inhalation208 mg/m³WorkersLDNELLong term Inhalation208 mg/m³WorkersSDNELLong term Inhalation208 mg/m³WorkersSDNELLong term Dermal1 mg/kg bw/dayGeneral populationSDNELLong term Dermal1 mg/kg bw/dayGeneral populationSDNELLong term Dermal1 mg/kg bw/dayGeneral populationSDNELLong term Dermal1 mg/kg bw/dayGeneral populationSDNELLong term Oral1 mg/kg bw/dayGeneral populationS <td>Systemic</td> <td></td> <td></td> <td>Long term Oral</td> <td>DNEL</td> <td></td>	Systemic			Long term Oral	DNEL	
Inhalation Long term Inhalationpopulation Workerspopulation WorkersDNELLong term Dermal108 mg/kg bw/dayGeneral populationSDNELLong term Dermal108 mg/kg bw/dayWorkersSDNELShort term Inhalation289 mg/m³WorkersSDNELShort term Inhalation289 mg/m³WorkersSDNELShort term Inhalation289 mg/m³WorkersSDNELLong term Dermal8.2 mg/kg bw/dayGeneral populationSDNELLong term Dermal8.2 mg/m³General populationSDNELLong term Dermal104 mg/m³General populationSDNELLong term Inhalation104 mg/m³General populationSDNELLong term Inhalation208 mg/m³WorkersSDNELLong term Inhalation208 mg/m³WorkersSDNELLong term DNEL208 mg/m³WorkersSCyclohexanoneDNELLong term Dermal1 mg/kg bw/dayGeneral populationSDNELLong term Dermal1 mg/kg bw/dayGeneral populationSDNELLong term Oral1.5 mg/kg bw/dayGeneral populationSDNELLong term Oral1.5 mg/kg bw/dayGeneral populationSDNELLong term Oral1.5 mg/kg bw/dayGeneral populationSDNELLong term Oral1.5 mg/kg bw/day						xylene
DNELLong term Inhalation77 mg/m³WorkersSDNELLong term Dermal108 mg/kg bw/dayGeneral populationSDNELLong term Dermal180 mg/kg bw/dayWorkersSDNELShort term Inhalation289 mg/m³WorkersSDNELShort term Inhalation289 mg/m³WorkersSDNELShort term Inhalation289 mg/m³WorkersSDNELCong term Dermal8.2 mg/kg bw/dayGeneral populationSDNELLong term Dermal13.67 mg/ kg bw/dayGeneral populationSDNELLong term Inhalation74.3 mg/m³ GeneralGeneral populationSDNELLong term Inhalation104 mg/m³ GeneralGeneral populationLong populationLong termDNELLong term Inhalation208 mg/m³ WorkersWorkersSDNELLong term Inhalation208 mg/m³ WorkersWorkersSDNELLong term Inhalation208 mg/m³ WorkersSDNELLong term Dermal Inhalation1 mg/kg Bow/dayGeneral populationSDNELLong term Dermal1 mg/kg Bow/dayGeneral populationSDNELLong term Dermal1 mg/kg Bow/dayGeneral populationSDNELLong term Oral1.5 mg/kg Bow/dayGeneral populationSDNELLong term Oral1.5 mg/kg Bow/dayGeneral populatio	Systemic		14.8 mg/m³		DNEL	
InhalationInhalationDNELLong term Dermal108 mg/kg bw/dayGeneral populationSDNELLong term Dermal180 mg/kg bw/dayWorkersSDNELShort term Inhalation289 mg/m³WorkersLiDNELShort term Inhalation289 mg/m³WorkersSDNELLong term Dermal8.2 mg/kg bw/dayGeneral populationSmethyl methacrylateDNELLong term Dermal8.2 mg/kg bw/dayGeneral populationSDNELLong term Dermal13.67 mg/ kg bw/dayWorkersSDNELLong term Dermal13.67 mg/ kg bw/dayWorkersSDNELLong term Inhalation104 mg/m³General populationLi populationLi populationSDNELLong term Inhalation104 mg/m³General populationLi populationLi populationLi populationSDNELLong term Inhalation208 mg/m³WorkersLi populationSDNELShort term Dermal1 mg/kg bw/dayGeneral populationSDNELShort term Oral1.5 mg/kg bw/dayGeneral populationSDNELShort term Oral1.5 mg/kg bw/dayGeneral populationSDNELLong term Oral1.5 mg/kg bw/dayGeneral populationSDNELLong term Oral1.5 mg/kg bw/dayGeneral populationSDNELLong term Oral <td></td> <td></td> <td></td> <td>Inhalation</td> <td></td> <td></td>				Inhalation		
DNELLong term Dermal108 mg/kg bw/dayGeneral populationSDNELLong term Dermal180 mg/kg bw/dayWorkersSDNELShort term inhalation289 mg/m³WorkersLDNELShort term inhalation289 mg/m³WorkersSDNELShort term inhalation289 mg/m³WorkersSDNELCong term Dermal8.2 mg/kg bw/dayGeneral populationSDNELLong term Dermal13.67 mg/ bw/dayWorkersSDNELLong term Dermal13.67 mg/ bw/dayWorkersSDNELLong term Dermal13.67 mg/ bw/dayGeneral populationSDNELLong term inhalation74.3 mg/m³General populationSDNELLong term inhalation208 mg/m³WorkersSDNELLong term inhalation208 mg/m³WorkersSDNELLong term Dermal1 mg/kg bw/dayGeneral populationScyclohexanoneDNELLong term Dermal1 mg/kg bw/dayGeneral populationSDNELLong term Oral1.5 mg/kg bw/dayGeneral populationSDNELSort term Oral1.5 mg/kg bw/dayGeneral populationSDNELLong term Oral1.5 mg/kg bw/dayGeneral populationSDNELLong term Oral1.5 mg/kg bw/dayGeneral populationSDNELLong term Oral1.5 mg/kg <br< td=""><td>Systemic</td><td>Workers</td><td>77 mg/m³</td><td>Long term</td><td>DNEL</td><td></td></br<>	Systemic	Workers	77 mg/m³	Long term	DNEL	
bw/daypopulationDNELLong term Dermal180 mg/kgDNELShort term289 mg/m³WorkersSInhalationDNELDNELShort term289 mg/m³WorkersSInhalationDNELDNELShort termInhalationB.2 mg/kgDNELLong term DermalBNELLong term DermalInhalation13.67 mg/WorkersSInhalationNorkersDNELLong termInhalation104 mg/m³GeneralpopulationDNELLong termInhalation104 mg/m³DNELLong termInhalation104 mg/m³ONELLong termInhalation104 mg/m³DNELLong termInhalation104 mg/m³DNELLong termInhalation208 mg/m³WorkersSInhalationDNELLong termInhalation1 mg/kgGeneralSInhalation1 mg/kgDNELLong term DermalInhalation1 mg/kgGeneralSDNELShort term OralInhalation1.5 mg/kgGeneralSDNELLong term OralI.5 mg/kgGeneralSoutianSDNELLong term OralI.5 mg/kgGeneralSoutianSDNELLong term OralI.5 mg/kg <t< td=""><td></td><td></td><td></td><td>Inhalation</td><td></td><td></td></t<>				Inhalation		
DNELLong term Dermal180 mg/kg bw/dayWorkersSDNELShort term Inhalation289 mg/m³WorkersLiDNELShort term Inhalation289 mg/m³WorkersSDNELShort term Inhalation289 mg/m³WorkersSDNELDNELLong term Dermal8.2 mg/kg bw/dayGeneral populationSDNELLong term Dermal13.67 mg/ kg bw/dayWorkersSDNELLong term Dermal104 mg/m³General populationSDNELLong term Inhalation104 mg/m³General populationLo populationDNELLong term Inhalation208 mg/m³WorkersSDNELLong term Inhalation208 mg/m³WorkersSDNELLong term Inhalation208 mg/m³WorkersSDNELLong term DNEL208 mg/m³WorkersSDNELLong term Dermal1 mg/kg bw/dayGeneral populationSDNELLong term Dermal1 mg/kg bw/dayGeneral populationSDNELShort term Oral1.5 mg/kg bw/dayGeneral populationSDNELLong term Oral1.5 mg/kg bw/dayGeneral populationSDNELLong term Oral1.5 mg/kg bw/dayGeneral populationS	Systemic	General	108 mg/kg	Long term Dermal	DNEL	
bw/day 289 mg/m³WorkersLi 289 mg/m³methyl methacrylateDNELShort term Inhalation289 mg/m³WorkersSDNELShort term Inhalation289 mg/m³WorkersSDNELLong term Dermal8.2 mg/kg bw/dayGeneral populationSDNELLong term Dermal13.67 mg/ kg bw/dayWorkersSDNELLong term Inhalation74.3 mg/m³General populationSDNELLong term Inhalation104 mg/m³General populationLi populationDNELLong term Inhalation208 mg/m³WorkersLi populationDNELLong term Inhalation208 mg/m³WorkersSDNELLong term Inhalation208 mg/m³WorkersSDNELLong term DNELShort term Dermal1 mg/kg populationGeneral populationSDNELLong term Dermal1 mg/kg bw/dayGeneral populationSDNELLong term Dermal1 mg/kg bw/dayGeneral populationSDNELLong term Oral1.5 mg/kg bw/dayGeneral populationSDNELLong term Oral1.5 mg/kg bw/dayGeneral populationSDNELLong term Oral1.5 mg/kg bw/dayGeneral populationS		population				
DNELShort term Inhalation289 mg/m³WorkersLi Workersmethyl methacrylateDNELShort term Inhalation289 mg/m³WorkersSDNELLong term Dermal8.2 mg/kg bw/dayGeneral populationSDNELLong term Dermal13.67 mg/ kg bw/dayWorkersSDNELLong term Inhalation74.3 mg/m³General populationSDNELLong term Inhalation104 mg/m³General populationLi populationDNELLong term Inhalation104 mg/m³General populationLi populationDNELLong term Inhalation208 mg/m³WorkersLi populationDNELLong term Inhalation208 mg/m³WorkersLi populationDNELLong term Inhalation1 mg/kg Bew/dayGeneral populationSDNELLong term Dermal1 mg/kg Bw/dayGeneral populationSDNELLong term Dermal1 mg/kg Bw/dayGeneral populationSDNELLong term Oral1.5 mg/kg Bw/dayGeneral populationSDNELLong term Oral1.5 mg/kg Bw/dayGeneral populationS	Systemic	Workers	180 mg/kg	Long term Dermal	DNEL	
Inhalation DNELDNELInhalation Short term Inhalation289 mg/m³WorkersSmethyl methacrylateDNELLong term Dermal8.2 mg/kg bw/dayGeneral populationSDNELLong term Dermal13.67 mg/ bw/dayWorkersSDNELLong term Dermal13.67 mg/ kg bw/dayWorkersSDNELLong term Inhalation74.3 mg/m³ populationGeneral populationSDNELLong term Inhalation104 mg/m³ populationGeneral populationLong populationLong populationDNELLong term Inhalation208 mg/m³ WorkersWorkersSDNELLong term Inhalation208 mg/m³ WorkersWorkersSDNELLong term DNEL208 mg/m³ Bhort term DermalWorkersSDNELShort term Dermal1 mg/kg Bow/dayGeneral populationSDNELLong term Oral1.5 mg/kg Bow/dayGeneral populationSDNELLong term Oral1.5 mg/kg Bow/dayGeneral populationSDNELLong term Oral1.5 mg/kg Bow/dayGeneral populationS			bw/day			
DNELShort term Inhalation289 mg/m³WorkersSmethyl methacrylateDNELLong term Dermal8.2 mg/kg bw/dayGeneral populationSDNELLong term Dermal13.67 mg/ kg bw/dayWorkersSDNELLong term Dermal13.67 mg/ kg bw/dayWorkersSDNELLong term Inhalation74.3 mg/m³General populationSDNELLong term Inhalation104 mg/m³General populationSDNELLong term Inhalation208 mg/m³WorkersLongDNELLong term Inhalation208 mg/m³WorkersLongDNELLong term Inhalation208 mg/m³WorkersSDNELLong term DNELShort term Dermal1 mg/kg bw/dayGeneral populationSDNELShort term Oral1.5 mg/kg bw/dayGeneral populationSDNELLong term Oral1.5 mg/kg bw/dayGeneral populationSDNELLong term Oral1.5 mg/kg bw/dayGeneral populationS	Local	Workers	289 mg/m ³	Short term	DNEL	
methyl methacrylateInhalation0DNELLong term Dermal8.2 mg/kg bw/dayGeneral populationSDNELLong term Dermal13.67 mg/ kg bw/dayWorkersSDNELLong term74.3 mg/m³General populationSDNELLong term104 mg/m³General populationLong termDNELLong term104 mg/m³General populationLong termDNELLong term208 mg/m³WorkersLong termDNELLong term208 mg/m³WorkersSInhalationDNELLong term208 mg/m³WorkersSDNELLong term208 mg/m³WorkersSInhalationDNELLong term208 mg/m³WorkersSDNELLong term Dermal1 mg/kg bw/dayGeneral populationSDNELLong term Dermal1 mg/kg bw/dayGeneral populationSDNELLong term Oral1.5 mg/kg bw/dayGeneral populationSDNELLong term Oral1.5 mg/kg bw/dayGeneral populationS				Inhalation		
methyl methacrylateDNELLong term Dermal8.2 mg/kg bw/dayGeneral populationSDNELLong term Dermal13.67 mg/ kg bw/dayWorkersSDNELLong term74.3 mg/m³General populationSDNELLong term104 mg/m³General populationSDNELLong term104 mg/m³General populationLong termDNELLong term208 mg/m³WorkersLong termDNELLong term208 mg/m³WorkersLong termDNELLong term208 mg/m³WorkersSInhalationDNELLong term208 mg/m³WorkersSDNELLong term208 mg/m³WorkersSInhalationDNELShort term Dermal1 mg/kg bw/dayGeneral populationSDNELLong term Dermal1 mg/kg bw/dayGeneral populationSDNELLong term Oral1.5 mg/kg bw/dayGeneral populationSDNELLong term Oral1.5 mg/kg bw/dayGeneral populationS	Systemic	Workers	289 mg/m ³	Short term	DNEL	
DNELLong term Dermalbw/daypopulationDNELLong term Dermal13.67 mg/ kg bw/dayWorkersSDNELLong term104 mg/m³General populationSInhalationDNELLong term104 mg/m³General populationLong populationDNELLong term208 mg/m³WorkersLong populationDNELLong term208 mg/m³WorkersLong populationDNELLong term208 mg/m³WorkersSInhalationDNELShort term Dermal1 mg/kg bw/dayGeneral populationSDNELLong term Dermal1 mg/kg bw/dayGeneral populationSDNELShort term Oral1.5 mg/kg bw/dayGeneral populationSDNELShort term Oral1.5 mg/kg bw/dayGeneral populationSDNELLong term Oral1.5 mg/kg bw/dayGeneral populationSDNELLong term Oral1.5 mg/kg bw/dayGeneral populationSDNELLong term Oral1.5 mg/kg bw/dayGeneral populationS				Inhalation		
DNELLong term Dermalbw/day 13.67 mg/ kg bw/daypopulation WorkersSDNELLong term74.3 mg/m³General populationSDNELLong term104 mg/m³General populationLong termDNELLong term104 mg/m³General populationLong termDNELLong term208 mg/m³WorkersLong termDNELLong term208 mg/m³WorkersLong termDNELLong term208 mg/m³WorkersSInhalationDNELShort term Dermal1 mg/kg bw/dayGeneral populationSDNELLong term Dermal1 mg/kg bw/dayGeneral populationSDNELShort term Oral1.5 mg/kg bw/dayGeneral populationSDNELLong term Oral1.5 mg/kg bw/dayGeneral populationSDNELLong term Oral1.5 mg/kg bw/dayGeneral populationS	Systemic	General		Long term Dermal	DNEL	methyl methacrylate
cyclohexanoneDNELLong term Inhalationkg bw/day 74.3 mg/m³General populationS populationDNELLong term Inhalation104 mg/m³General populationLong termDNELLong term Inhalation208 mg/m³WorkersLong termDNELLong term Inhalation208 mg/m³WorkersS populationDNELLong term Inhalation208 mg/m³WorkersS populationDNELLong term Inhalation208 mg/m³WorkersS populationDNELLong term Dermal1 mg/kgGeneral populationS populationDNELLong term Dermal1 mg/kgGeneral populationS populationDNELShort term Oral1.5 mg/kgGeneral populationS populationDNELLong term Oral1.5 mg/kgGeneral populationS population		population	bw/day			
DNELLong term Inhalation74.3 mg/m³General populationSDNELLong term Inhalation104 mg/m³General populationLong termDNELLong term Inhalation208 mg/m³WorkersLong termDNELLong term Inhalation208 mg/m³WorkersSDNELLong term Inhalation208 mg/m³WorkersSDNELLong term Inhalation208 mg/m³WorkersSDNELLong term Inhalation1 mg/kgGeneral populationSDNELShort term Dermal1 mg/kgGeneral populationSDNELLong term Oral1.5 mg/kgGeneral populationSDNELLong term Oral1.5 mg/kgGeneral populationSDNELLong term Oral1.5 mg/kgGeneral populationSDNELLong term Oral1.5 mg/kgGeneral populationS	Systemic	Workers		Long term Dermal	DNEL	
InhalationpopulationDNELLong term104 mg/m³General populationDNELLong term208 mg/m³WorkersLongDNELLong term208 mg/m³WorkersLongDNELLong term208 mg/m³WorkersSInhalationDNELShort term Dermal1 mg/kgGeneral populationSDNELShort term Dermal1 mg/kgGeneral populationSDNELLong term Dermal1 mg/kgGeneral populationSDNELLong term Dermal1.5 mg/kgGeneral populationSDNELShort term Oral1.5 mg/kgGeneral populationSDNELLong term Oral1.5 mg/kgGeneral populationSDNELLong term Oral1.5 mg/kgGeneral populationS						
DNELLong term Inhalation104 mg/m³General populationLong term populationDNELLong term Inhalation208 mg/m³WorkersLong termDNELLong term Inhalation208 mg/m³WorkersSCyclohexanoneDNELShort term Dermal1 mg/kg bw/dayGeneral populationSDNELLong term Dermal1 mg/kg bw/dayGeneral populationSDNELLong term Dermal1 mg/kg bw/dayGeneral populationSDNELShort term Oral1.5 mg/kg bw/dayGeneral populationSDNELLong term Oral1.5 mg/kg bw/dayGeneral populationS	Systemic		74.3 mg/m ³		DNEL	
Inhalation Long term Inhalation208 mg/m³population WorkersDNELLong term Inhalation208 mg/m³WorkersLong WorkersDNELLong term Inhalation208 mg/m³WorkersSCyclohexanoneDNELShort term Dermal1 mg/kg bw/dayGeneral populationSDNELLong term Dermal1 mg/kg bw/dayGeneral populationSDNELLong term Oral1.5 mg/kg bw/dayGeneral populationSDNELShort term Oral1.5 mg/kg bw/dayGeneral populationSDNELLong term Oral1.5 mg/kg bw/dayGeneral populationS						
DNELLong term Inhalation208 mg/m³WorkersLongDNELLong term Inhalation208 mg/m³WorkersS208 mg/m³WorkersSNELLong term Inhalation208 mg/m³WorkersSDNELShort term Dermal1 mg/kg bw/dayGeneral populationSDNELLong term Dermal1 mg/kg bw/dayGeneral populationSDNELShort term Oral1.5 mg/kg bw/dayGeneral populationSDNELLong term Oral1.5 mg/kg bw/dayGeneral populationSDNELLong term Oral1.5 mg/kg bw/dayGeneral populationS	Local		104 mg/m³		DNEL	
cyclohexanone DNEL Inhalation Long term 208 mg/m ³ Workers S Inhalation DNEL Short term Dermal 1 mg/kg General S bw/day population DNEL Long term Dermal 1 mg/kg General S bw/day population DNEL Short term Oral 1.5 mg/kg General S bw/day population S DNEL Long term Oral 1.5 mg/kg General S bw/day population S bw/day population S bw/day population S bw/day population S bw/day population S bw/day Seneral S						
cyclohexanoneDNELLong term Inhalation208 mg/m³WorkersScyclohexanoneDNELShort term Dermal1 mg/kg bw/dayGeneral populationSDNELLong term Dermal1 mg/kg bw/dayGeneral populationSDNELShort term Oral1.5 mg/kg bw/dayGeneral populationSDNELShort term Oral1.5 mg/kg bw/dayGeneral populationSDNELLong term Oral1.5 mg/kg bw/dayGeneral populationS	Local	Workers	208 mg/m ³	-	DNEL	
cyclohexanoneInhalationI mg/kg bw/dayGeneral populationSDNELShort term Dermal1 mg/kg bw/dayGeneral populationSDNELLong term Dermal1 mg/kg bw/dayGeneral populationSDNELShort term Oral1.5 mg/kg bw/dayGeneral populationSDNELLong term Oral1.5 mg/kg bw/dayGeneral populationSDNELLong term Oral1.5 mg/kg bw/dayGeneral populationS						
cyclohexanoneDNELShort term Dermal1 mg/kg bw/dayGeneral populationSDNELLong term Dermal1 mg/kgGeneral bw/daySDNELShort term Oral1.5 mg/kgGeneral populationSDNELShort term Oral1.5 mg/kgGeneral populationSDNELLong term Oral1.5 mg/kgGeneral populationSDNELLong term Oral1.5 mg/kgGeneral populationS	Systemic	Workers	208 mg/m ³		DNEL	
DNELLong term Dermalbw/daypopulationDNELLong term Dermal1 mg/kgGeneralSbw/daypopulation1.5 mg/kgGeneralSbw/dayDNELShort term Oral1.5 mg/kgGeneralSbw/daypopulation1.5 mg/kgGeneralSbw/daypopulationSbw/daypopulationbw/daypopulationSbw/daypopulationbw/daypopulationSbw/daypopulation						
DNELLong term Dermal1 mg/kg bw/dayGeneral populationSDNELShort term Oral1.5 mg/kg bw/dayGeneral populationSDNELLong term Oral1.5 mg/kg bw/dayGeneral populationSDNELLong term Oral1.5 mg/kg bw/dayGeneral populationS	Systemic			Short term Dermal	DNEL	cyclohexanone
DNELShort term Oralbw/daypopulationDNELShort term Oral1.5 mg/kgGeneralSbw/daypopulation1.5 mg/kgGeneralSbw/daybw/daypopulationSbw/daypopulationSbw/daypopulationSbw/daypopulationSbw/daypopulationS						
DNELShort term Oral1.5 mg/kg bw/dayGeneral populationSDNELLong term Oral1.5 mg/kg bw/dayGeneral populationS	Systemic			Long term Dermal	DNEL	
DNEL Long term Oral bw/day population 1.5 mg/kg General S bw/day population						
DNELLong term Oral1.5 mg/kgGeneralSbw/daypopulation	Systemic		1.5 mg/kg	Short term Oral	DNEL	
DNEL Long term Oral 1.5 mg/kg General S bw/day population			bw/day			
bw/day population	Systemic		1.5 mg/kg	Long term Oral	DNEL	
e of issue/Date of revision :1-11-2022 Version :1.01		population		-		
e of issue/Date of revision : 1-11-2022 Version : 1.01	<u> </u>				<u> </u>	
		: 1.01				
e of previous issue : 1-10-2022 8/19	AkzoNo		8/19		-2022	e of previous issue : 1-1

DNEL	Short term Dermal	4 mg/kg	Workers	Systemic
		bw/day		
DNEL	Long term Dermal	4 mg/kg bw/day	Workers	Systemic
DNEL	Long term	10 mg/m ³	General	Systemic
	Inhalation	_	population	
DNEL	Long term	20 mg/m ³	General	Local
	Inhalation		population	
DNEL	Short term	20 mg/m ³	General	Systemic
	Inhalation		population	
DNEL	Short term	40 mg/m³	General	Local
	Inhalation		population	
DNEL	Long term	40 mg/m³	Workers	Local
	Inhalation			
DNEL	Long term	40 mg/m³	Workers	Systemic
	Inhalation			
DNEL	Short term	80 mg/m³	Workers	Local
	Inhalation			
DNEL	Short term	80 mg/m³	Workers	Systemic
	Inhalation			

PNECs

No PNECs available.

8.2 Exposure controls			
Appropriate engineering controls	ventilation or other enc contaminants below a controls also need to k	e ventilation. Use process enclosure gineering controls to keep worker exp ny recommended or statutory limits. keep gas, vapor or dust concentration explosion-proof ventilation equipmen	posure to airborne The engineering ns below any lower
Individual protection meas	ures		
Hygiene measures	before eating, smoking Appropriate technique Wash contaminated cl	s and face thoroughly after handling g and using the lavatory and at the er s should be used to remove potentia lothing before reusing. Ensure that e ose to the workstation location.	nd of the working period. Illy contaminated clothing.
Eye/face protection	assessment indicates gases or dusts. If con	ying with an approved standard shou this is necessary to avoid exposure t tact is possible, the following protect in indicates a higher degree of protec	to liquid splashes, mists, ion should be worn,
Skin protection			
Hand protection	be worn at all times wh this is necessary. Cor check during use that should be noted that th different for different g	pervious gloves complying with an a hen handling chemical products if a r nsidering the parameters specified by the gloves are still retaining their pro- he time to breakthrough for any glove love manufacturers. In the case of n he protection time of the gloves canno	isk assessment indicates y the glove manufacturer, tective properties. It e material may be nixtures, consisting of
	protection class of 6 (k recommended. Recor When only brief conta (breakthrough time >3 Recommended gloves	equently repeated contact may occur preakthrough time >480 minutes accor mmended gloves: Viton ® or Nitrile, t ct is expected, a glove with protection 00 minutes according to EN374) is rea s: Nitrile, thickness ≥ 0.12 mm. aced regularly and if there is any sign	ording to EN374) is thickness ≥ 0.38 mm. n class of 2 or higher commended.
Date of issue/Date of revision	: 1-11-2022	Version : 1.01	
Date of previous issue	: 1-10-2022	9/19	AkzoNobel

SECTION 8: Exposure controls/personal protection

		The performance or effectiveness of the glove may be reduced by physical/ chemical damage and poor maintenance.
		The user must check that the final choice of type of glove selected for handling this product is the most appropriate and takes into account the particular conditions of use, as included in the user's risk assessment.
Body protection	:	Personal protective equipment for the body should be selected based on the task being performed and the risks involved and should be approved by a specialist before handling this product. When there is a risk of ignition from static electricity, wear anti-static protective clothing. For the greatest protection from static discharges, clothing should include anti-static overalls, boots and gloves. Refer to European Standard EN 1149 for further information on material and design requirements and test methods.
Other skin protection	:	Appropriate footwear and any additional skin protection measures should be selected based on the task being performed and the risks involved and should be approved by a specialist before handling this product.
Respiratory protection	:	Based on the hazard and potential for exposure, select a respirator that meets the appropriate standard or certification. Respirators must be used according to a respiratory protection program to ensure proper fitting, training, and other important aspects of use.
Environmental exposure controls	:	Emissions from ventilation or work process equipment should be checked to ensure they comply with the requirements of environmental protection legislation. In some cases, fume scrubbers, filters or engineering modifications to the process equipment will be necessary to reduce emissions to acceptable levels.

SECTION 9: Physical and chemical properties

9.1 Information on basic physical and chemical properties

Appearance

Appearance		
Physical state	:	Liquid.
Color	:	Brown.
Odor	:	Characteristic.
Odor threshold	:	Not available.
рН	:	Not available.
Melting point/freezing point	:	Not available.
Initial boiling point and boiling range	:	Not available.
Flash point	:	Closed cup: 28°C
Evaporation rate	:	Not available.
Flammability (solid, gas)	:	Not available.
Upper/lower flammability or explosive limits	:	Not available.
Vapor pressure	:	Not available.
Vapor density	:	Highest known value: 4.6 (Air = 1) (2-methoxy-1-methylethyl acetate). Weighted average: 4.01 (Air = 1)
Density	:	1.377 g/cm³
Solubility(ies)	:	Insoluble in the following materials: cold water.
Partition coefficient: n-octanol/ water	:	Not available.
Auto-ignition temperature	:	Not available.
Decomposition temperature	:	Not available.
Viscosity	:	Kinematic (room temperature): 7.26 cm²/s Kinematic (40°C): 1.01 cm²/s

SECTION 10: Stability and reactivity

10.1 Reactivity	: No specific test data related to reactivity available for this product or its ingredients.
ion Reactivity	
10.2 Chamical stability	. The product is stable
10.2 Chemical stability	: The product is stable.
40.2 Dessibility of	
10.3 Possibility of hazardous reactions	: Under normal conditions of storage and use, hazardous reactions will not occur.
10.4 Conditions to avoid	· Avoid all possible sources of ignition (spork or flame). Do not prossurize, out wold
10.4 Conditions to avoid	: Avoid all possible sources of ignition (spark or flame). Do not pressurize, cut, weld, braze, solder, drill, grind or expose containers to heat or sources of ignition.
10.5 Incompatible materials	: Reactive or incompatible with the following materials:
· · · · · · · · · · · · · · · · · · ·	oxidizing materials
10.6 Hazardous	: Under normal conditions of storage and use, hazardous decomposition products
decomposition products	should not be produced.

SECTION 11: Toxicological information

11.1 Information on toxicological effects

Acute toxicity

P-butyl acetateLC50 Inhalation Gas. LC50 Inhalation Vapo LD50 Dermal LD50 Oral LD50 Inhalation Vapo LD50 Dermal LD50 Intraperitoneal LD50 Intraperitoneal LD50 Intraperitoneal LD50 Oral LD50 Oral LD50 Intraperitoneal LD50 Oral LD50 Oral LD50 Intraperitoneal LD50 Oral LD50 Intraperitoneal LD50	Species	Dose	Exposure
cyclohexanone cycloh	Rat	390 ppm	4 hours
cyclohexanone cy	or Mouse	6 g/m ³	2 hours
LD50 OralReaction mass of ethylbenzene and xylene methyl methacrylateLC50 Inhalation Gas.LC50 Inhalation Vapo LC50 Inhalation Vapo LD50 Dermal LD50 Intraperitoneal LD50 Intraperitoneal LD50 Oral LD50 Intraperitoneal LD50 Intrape	Rabbit	>17600 mg/kg	-
Reaction mass of ethylbenzene and xylene methyl methacrylateLD50 Oral LD50 Oral LC50 Inhalation Gas.LC50 Inhalation Vapo LD50 Dermal LD50 Intraperitoneal LD50 Intraperitoneal LD50 Oral LD50 Intraperitoneal LD50 Intraperitoneal 	Mouse	1230 mg/kg	-
Reaction mass of ethylbenzene and xylene methyl methacrylateLD50 Oral LC50 Inhalation Gas.LC50 Inhalation Vapo LC50 Inhalation Vapo LD50 Dermal LD50 Intraperitoneal LD50 Intraperitoneal LD50 Intraperitoneal LD50 Oral LD50 Oral LD50 Oral LD50 Oral LD50 Oral LD50 Oral LD50 Subcutaneous LD50 Subcutaneous LD50 Subcutaneous LD50 Intraperitoneal LD50 Intraperitoneal LD50 Intraperitoneal LD50 Subcutaneous LD50 Intraperitoneal LD50 Intraperitoneal ID50 Intraperitoneal ID50 Intraperitoneal ID50 Intraperitoneal ID50 Intraperitoneal ID50 Intraperitoneal ID50 Intraperitoneal ID50 Intraperitoneal ID50 Intraper	Guinea pig	4700 mg/kg	-
Reaction mass of ethylbenzene and xylene methyl methacrylateLD50 Oral LC50 Inhalation Vapor LC50 Inhalation Vapor LD50 Dermal LD50 Intraperitoneal LD50 Intraperitoneal LD50 Intraperitoneal LD50 Oral LD50 Oral LD50 Oral LD50 Oral LD50 Oral LD50 Oral LD50 Subcutaneous LD50 Subcutaneous LD50 Subcutaneous LD50 Intraperitoneal LD50 Intraperitoneal LD50 Oral LD50 Oral LD50 Oral LD50 Oral LD50 Oral LD50 Oral LD50 Intraperitoneal LD50 Intraperitoneal ID50 Intraperitoneal ID50 Intraperitoneal ID50 Intraperitoneal ID50 Intraperitoneal ID50 Intraperitoneal ID50 Intraperitoneal ID50 Intrape	Mouse	6 g/kg	-
Reaction mass of ethylbenzene and xylene methyl methacrylate LC50 Inhalation Vapo LC50 Inhalation Vapo LC50 Inhalation Vapo LC50 Inhalation Vapo LD50 Dermal LD50 Intraperitoneal LD50 Intraperitoneal LD50 Oral LD50 Oral LD50 Oral LD50 Subcutaneous LD50 Subcutaneous LD50 Subcutaneous LD50 Subcutaneous LD50 Subcutaneous LD50 Intraperitoneal LD50 Intraperitoneal	Rabbit	3200 mg/kg	-
ethylbenzene and xylene methyl methacrylate LC50 Inhalation Vapo LD50 Dermal LD50 Intraperitoneal LD50 Intraperitoneal LD50 Intraperitoneal LD50 Oral LD50 Oral LD50 Oral LD50 Oral LD50 Subcutaneous LD50 Subcutaneous LD50 Subcutaneous LD50 Subcutaneous LD50 Subcutaneous LD50 Subcutaneous LD50 Intraperitoneal LD50 Intraperitoneal	Rat	10768 mg/kg	-
methyl methacrylate LC50 Inhalation Vapo LC50 Inhalation Vapo LD50 Dermal LD50 Intraperitoneal LD50 Intraperitoneal LD50 Intraperitoneal LD50 Oral LD50 Oral LD50 Oral LD50 Oral LD50 Subcutaneous LD50 Subcutaneous LD50 Subcutaneous LD50 Subcutaneous LD50 Subcutaneous LD50 Intraperitoneal LD50 Intraperitoneal	Rat	5000 ppm	4 hours
LC50 Inhalation Vapo LD50 Dermal LD50 Intraperitoneal LD50 Intraperitoneal LD50 Intraperitoneal LD50 Oral LD50 Oral LD50 Oral LD50 Subcutaneous LD50 Subcutaneous LD50 Subcutaneous LD50 Subcutaneous LD50 Subcutaneous LD50 Subcutaneous LD50 Intraperitoneal LD50 Intraperito	r Mouse	18500 mg/m ³	2 hours
LD50 Dermal LD50 Intraperitoneal LD50 Intraperitoneal LD50 Intraperitoneal LD50 Oral LD50 Oral LD50 Oral LD50 Oral LD50 Subcutaneous LD50 Subcutaneous LD50 Subcutaneous LD50 Subcutaneous LD50 Subcutaneous LD50 Inhalation Gas. LD50 Intraperitoneal LD50 Intraperitoneal LD		78000 mg/m ³	4 hours
LD50 Intraperitoneal LD50 Intraperitoneal LD50 Intraperitoneal LD50 Oral LD50 Oral LD50 Oral LD50 Oral LD50 Subcutaneous LD50 Subcutaneous LD50 Subcutaneous LD50 Subcutaneous LD50 Subcutaneous LD50 Intraperitoneal LD50 Oral LD50 Oral LD50 Oral	Rabbit	>5 g/kg	-
LD50 Intraperitoneal LD50 Intraperitoneal LD50 Oral LD50 Oral LD50 Oral LD50 Oral LD50 Oral LD50 Subcutaneous LD50 Subcutaneous LD50 Subcutaneous LD50 Subcutaneous LD50 Subcutaneous LD50 Intraperitoneal LD50 Oral LD50 Oral LD50 Oral	Guinea pig	1890 mg/kg	-
LD50 Intraperitoneal LD50 Oral LD50 Oral LD50 Oral LD50 Oral LD50 Oral LD50 Subcutaneous LD50 Subcutaneous LD50 Subcutaneous LD50 Subcutaneous LD50 Subcutaneous LD50 Intraperitoneal LD50	Mouse	945 mg/kg	-
LD50 Oral LD50 Oral LD50 Oral LD50 Oral LD50 Subcutaneous LD50 Subcutaneous LD50 Subcutaneous LD50 Subcutaneous LD50 Subcutaneous LD50 Intraperitoneal LD50 Intraperit	Rat	1328 mg/kg	-
LD50 Oral LD50 Oral LD50 Oral LD50 Subcutaneous LD50 Subcutaneous LD50 Subcutaneous LD50 Subcutaneous LD50 Subcutaneous LD50 Inhalation Gas. LD50 Dermal LD50 Intraperitoneal LD50 Intraper	Guinea pig	5954 mg/kg	-
LD50 Oral LD50 Oral LD50 Subcutaneous LD50 Subcutaneous LD50 Subcutaneous LD50 Subcutaneous LD50 Subcutaneous LD50 Inhalation Gas. LD50 Dermal LD50 Intraperitoneal LD50 Intraperitoneal LD	Mouse	3625 mg/kg	-
LD50 Oral LD50 Subcutaneous LD50 Subcutaneous LD50 Subcutaneous LD50 Subcutaneous LD50 Inhalation Gas. LD50 Dermal LD50 Intraperitoneal LD50 Intraperitoneal LD50 Intraperitoneal LD50 Intraperitoneal LD50 Intraperitoneal LD50 Intraperitoneal LD50 Intraperitoneal LD50 Intraperitoneal LD50 Intraperitoneal LD50 Oral LD50 Oral LD50 Oral	Rabbit	8700 mg/kg	-
LD50 Subcutaneous LD50 Subcutaneous LD50 Subcutaneous LD50 Subcutaneous LC50 Inhalation Gas. LD50 Dermal LD50 Intraperitoneal LD50 Intraperitoneal LD50 Intraperitoneal LD50 Intraperitoneal LD50 Intraperitoneal LD50 Intraperitoneal LD50 Intraperitoneal LD50 Intraperitoneal LD50 Oral LD50 Oral LD50 Oral	Rat	7872 mg/kg	_
LD50 Subcutaneous LD50 Subcutaneous LC50 Inhalation Gas. LD50 Dermal LD50 Intraperitoneal LD50 Intraperitoneal LD50 Intraperitoneal LD50 Intraperitoneal LD50 Intraperitoneal LD50 Intraperitoneal LD50 Intraperitoneal LD50 Intraperitoneal LD50 Oral LD50 Oral LD50 Oral	Guinea pig	5954 mg/kg	-
cyclohexanone LD50 Subcutaneous LC50 Inhalation Gas. LD50 Dermal LD50 Intraperitoneal LD50 Intraperitoneal LD50 Intraperitoneal LD50 Intraperitoneal LD50 Intraperitoneal LD50 Intraperitoneal LD50 Intraperitoneal LD50 Intraperitoneal LD50 Oral LD50 Oral LD50 Oral	Mouse	5954 mg/kg	-
cyclohexanone LC50 Inhalation Gas. LD50 Dermal LD50 Intraperitoneal LD50 Intraperitoneal LD50 Intraperitoneal LD50 Intraperitoneal LD50 Intraperitoneal LD50 Intraperitoneal LD50 Intraperitoneal LD50 Oral LD50 Oral LD50 Oral	Rat	7088 mg/kg	-
LD50 Dermal LD50 Intraperitoneal LD50 Intraperitoneal LD50 Intraperitoneal LD50 Intraperitoneal LD50 Intraperitoneal LD50 Intraperitoneal LD50 Intraperitoneal LD50 Oral LD50 Oral LD50 Oral		8000 ppm	4 hours
LD50 Intraperitoneal LD50 Intraperitoneal LD50 Intraperitoneal LD50 Intraperitoneal LD50 Intraperitoneal LD50 Intraperitoneal LD50 Oral LD50 Oral LD50 Oral	Rabbit	1 mL/kg	-
LD50 Intraperitoneal LD50 Intraperitoneal LD50 Intraperitoneal LD50 Intraperitoneal LD50 Intraperitoneal LD50 Intraperitoneal LD50 Oral LD50 Oral LD50 Oral	Guinea pig	930 mg/kg	-
LD50 Intraperitoneal LD50 Intraperitoneal LD50 Intraperitoneal LD50 Intraperitoneal LD50 Intraperitoneal LD50 Oral LD50 Oral LD50 Oral	Mouse	1230 mg/kg	-
LD50 Intraperitoneal LD50 Intraperitoneal LD50 Intraperitoneal LD50 Intraperitoneal LD50 Oral LD50 Oral LD50 Oral	Mouse	1230 mg/kg	-
LD50 Intraperitoneal LD50 Intraperitoneal LD50 Intraperitoneal LD50 Oral LD50 Oral LD50 Oral	Rabbit	1540 mg/kg	-
LD50 Intraperitoneal LD50 Intraperitoneal LD50 Oral LD50 Oral LD50 Oral	Rabbit	1540 mg/kg	-
LD50 Intraperitoneal LD50 Oral LD50 Oral LD50 Oral	Rat	1130 mg/kg	-
LD50 Oral LD50 Oral LD50 Oral	Rat	1130 mg/kg	-
LD50 Oral LD50 Oral	Mouse	1400 mg/kg	-
	Rat	1800 mg/kg	-
	Rat	1620 uL/kg	-
LD50 Subcutaneous	Rat	2170 mg/kg	-
e of issue/Date of revision : 1-11-2022		on : 1.01	

11/19



SECTION 11: Toxicological information

Conclusion/Summary : Not available.

Irritation/Corrosion	

Product/ingredient name	Result	Species	Score	Exposure	Observation
-butyl acetate	Eyes - Moderate irritant	Rabbit	-	100 mg	-
	Skin - Moderate irritant	Rabbit	-	24 hours 500	-
				mg	
Reaction mass of	Eyes - Mild irritant	Rabbit	-	87 mg	-
ethylbenzene and xylene					
	Eyes - Severe irritant	Rabbit	-	24 hours 5	-
				mg	
	Skin - Mild irritant	Rat	-	8 hours 60 UI	-
	Skin - Moderate irritant	Rabbit	-	24 hours 500	-
				mg	
	Skin - Moderate irritant	Rabbit	-	100 %	-
cyclohexanone	Eyes - Severe irritant	Rabbit	-	24 hours 250	-
				ug	
	Eyes - Severe irritant	Rabbit	-	20 mg	-
	Skin - Mild irritant	Rabbit	-	500 mg	-
Conclusion/Summary	: Not available.	I	1	I	1
Sensitization					

Sensitization		
Conclusion/Summary	:	Not available.
<u>Mutagenicity</u>		
Conclusion/Summary	:	Not available.
Carcinogenicity		
Conclusion/Summary	:	Not available.
Reproductive toxicity		
Conclusion/Summary	:	Not available.
Teratogenicity		
Conclusion/Summary	:	Not available.

Specific target organ toxicity (single exposure)

Product/ingredient name	Category	Route of exposure	Target organs
n -butyl acetate Reaction mass of ethylbenzene and xylene	Category 3 Category 3	-	Narcotic effects Respiratory tract irritation
2-methoxy-1-methylethyl acetate methyl methacrylate	Category 3 Category 3	-	Narcotic effects Respiratory tract irritation

Specific target organ toxicity (repeated exposure)

Product/ingredient name	Category	Route of exposure	Target organs
Reaction mass of ethylbenzene and xylene	Category 2	-	-

Aspiration hazard

Product/ingredient name	Result
Reaction mass of ethylbenzene and xylene Hydrocarbons, C11-C14, n-alkanes, isoalkanes, cyclics, <2% aromatics	ASPIRATION HAZARD - Category 1 ASPIRATION HAZARD - Category 1

Information on the likely : Not available. routes of exposure



SECTION 11: Toxicological information

SECTION 11: Toxico	logical information
Potential acute health effects	<u>S</u>
Eye contact	: Causes serious eye irritation.
Inhalation	: Can cause central nervous system (CNS) depression. May cause drowsiness or dizziness.
Skin contact	: Causes skin irritation.
Ingestion	: Can cause central nervous system (CNS) depression.
Symptoms related to the phy	vsical, chemical and toxicological characteristics
Eye contact	: Adverse symptoms may include the following: pain or irritation watering redness
Inhalation	: Adverse symptoms may include the following: nausea or vomiting headache drowsiness/fatigue dizziness/vertigo unconsciousness
Skin contact	: Adverse symptoms may include the following: irritation redness
Ingestion	: No specific data.
Delayed and immediate effect	cts and also chronic effects from short and long term exposure
Short term exposure	
Potential immediate effects	: Not available.
Potential delayed effects	: Not available.
<u>Long term exposure</u>	
Potential immediate effects	: Not available.
Potential delayed effects	: Not available.
Potential chronic health eff	ects
Not available.	
Conclusion/Summary	: Not available.
General	: May cause damage to organs through prolonged or repeated exposure.
Carcinogenicity	: No known significant effects or critical hazards.
Mutagenicity	: No known significant effects or critical hazards.
Reproductive toxicity	: No known significant effects or critical hazards.
Other information	: Not available.

SECTION 12: Ecological information

12.1 Toxicity

There are no data available on the mixture itself. Do not allow to enter drains or watercourses.

The mixture has been assessed following the summation method of the CLP Regulation (EC) No 1272/2008 and is not classified as hazardous to the environment, but contains substance(s) hazardous to the environment. See section 3 for details.

Date of issue/Date of revision	: 1-11-2022	Version : 1.01	
Date of previous issue	: 1-10-2022	13/19	AkzoNobel

SECTION 12: Ecological information

Product/ingredient name	Result	Species	Exposure
p-butyl acetate	Acute LC50 32 mg/l Marine water	Crustaceans - Artemia salina	48 hours
-	Acute LC50 100000 µg/l Fresh water	Fish - Lepomis macrochirus	96 hours
	Acute LC50 18000 µg/l Fresh water	Fish - Pimephales promelas	96 hours
	Acute LC50 185000 µg/l Marine water	Fish - Menidia beryllina	96 hours
	Acute LC50 62000 µg/l Fresh water	Fish - Danio rerio	96 hours
Reaction mass of ethylbenzene and xylene	Acute LC50 13400 µg/l Fresh water	Fish - Pimephales promelas	96 hours
methyl methacrylate	Acute LC50 191000 µg/l Fresh water	Fish - Lepomis macrochirus - Juvenile (Fledgling, Hatchling, Weanling)	96 hours
	Acute LC50 159100 µg/l Fresh water	Fish - Pimephales promelas	96 hours
	Acute LC50 160200 µg/l Fresh water	Fish - Pimephales promelas	96 hours
	Acute LC50 150000 µg/l Fresh water	Fish - Pimephales promelas - Adult	96 hours
	Acute LC50 130000 µg/l Fresh water	Fish - Pimephales promelas - Adult	96 hours
cyclohexanone	Acute EC50 32.9 mg/l Fresh water	Algae - Chlamydomonas reinhardtii - Exponential growth phase	72 hours
	Acute LC50 630000 µg/l Fresh water	Fish - Pimephales promelas	96 hours
	Acute LC50 527000 µg/l Fresh water	Fish - Pimephales promelas	96 hours
	Acute LC50 732000 µg/l Fresh water	Fish - Pimephales promelas	96 hours

Conclusion/Summary

: Not available.

12.2 Persistence and degradability

Conclusion/Summary : Not available.

12.3 Bioaccumulative potential

Product/ingredient name	LogPow	BCF	Potential
-butyl acetate	2.3	-	low
Reaction mass of ethylbenzene and xylene	3.12	8.1 to 25.9	low
2-methoxy-1-methylethyl acetate	1.2	-	low
methyl methacrylate cyclohexanone	1.38 0.86	-	low low

12.4 Mobility in soil

Soil/water partition coefficient (K _{oc})	: Not available.
Mobility	: Not available.

12.5 Results of PBT and vPvB assessment

This mixture does not contain any substances that are assessed to be a PBT or a vPvB.

12.6 Other adverse effects : No known significant effects or critical hazards.



SECTION 13: Disposal considerations

The information in this section contains generic advice and guidance. The list of Identified Uses in Section 1 should be consulted for any available use-specific information provided in the Exposure Scenario(s).

13.1 Waste treatment methods

<u>Product</u>	
Methods of disposal	: The generation of waste should be avoided or minimized wherever possible. Disposal of this product, solutions and any by-products should at all times comply with the requirements of environmental protection and waste disposal legislation and any regional local authority requirements. Dispose of surplus and non- recyclable products via a licensed waste disposal contractor. Waste should not be disposed of untreated to the sewer unless fully compliant with the requirements of all authorities with jurisdiction.
Hazardous waste	: The classification of the product may meet the criteria for a hazardous waste.
Disposal considerations	 Do not allow to enter drains or watercourses. Dispose of according to all federal, state and local applicable regulations. If this product is mixed with other wastes, the original waste product code may no longer apply and the appropriate code should be assigned. For further information, contact your local waste authority.

European waste catalogue (EWC)

The European Waste Catalogue classification of this product, when disposed of as waste, is:

Waste code	Waste designation
EWC 08 01 11*	waste paint and varnish containing organic solvents or other hazardous substances
Packaging	
Methods of disposal	: The generation of waste should be avoided or minimized wherever possible. Waste packaging should be recycled. Incineration or landfill should only be considered when recycling is not feasible.
Disposal considerations	 Using information provided in this safety data sheet, advice should be obtained from the relevant waste authority on the classification of empty containers. Empty containers must be scrapped or reconditioned. Dispose of containers contaminated by the product in accordance with local or national legal provisions.
Special precautions	: This material and its container must be disposed of in a safe way. Care should be taken when handling emptied containers that have not been cleaned or rinsed out. Empty containers or liners may retain some product residues. Vapor from product residues may create a highly flammable or explosive atmosphere inside the container. Do not cut, weld or grind used containers unless they have been cleaned thoroughly internally. Avoid dispersal of spilled material and runoff and contact with soil, waterways, drains and sewers.

SECTION 14: Transport information

ADR/RID	IMDG		ΙΑΤΑ
UN1263	UN1263	UN1263	
PAINT	PAINT	PAINT	
3	3	3	
vision : 1-11-2022	Versio 15/19		AkzoNobel
	UN1263 PAINT 3 VVVVVVVVVVVVVVVVVVVVVVVVVVVVVVVVVVV	UN1263 UN1263 PAINT PAINT 3 3 III III	UN1263UN1263UN1263PAINTPAINTPAINT333IIIIIIIII

SECTION 14: T	ranspo	rt information				
14.5 Environmental hazards	No.		No.		No.	
Additional informat	tion					
ADR/RID			50 L according to 2.2		d is not subject to regulation in	
IMDG		-		•	d is not subject to regulation in	
14.6 Special precaut user	tions for	-	. Ensure that persons		rt in closed containers that are g the product know what to do in	
14.7 Transport in bu according to IMO instruments	ılk	: Not applicable.				
SECTION 15: F	Regulate	ory information	1			
15.1 Safety, health a	nd enviror	mental regulations/l	legislation specific f	or the subs	stance or mixture	

EU Regulation (EC) No. 1907/2006 (REACH)

Annex XIV - List of substances subject to authorization

Annex XIV	-	
None of the components a	re listed.	
Substances of very high	<u>concern</u>	
None of the components a	re listed.	
Annex XVII - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, mixtures and articles	: Not applicable.	
Other EU regulations		
VOC		ective 2004/42/EC on VOC apply to this product. Refer to the echnical data sheet for further information.
VOC for Ready-for-Use Mixture	: Not applicable.	
Industrial emissions (integrated pollution prevention and control) - Air	: Not listed	
Industrial emissions (integrated pollution prevention and control) - Water	: Not listed	
Ozone depleting substanc	<u>es (1005/2009/EU)</u>	
Not listed.		
Prior Informed Consent (P	IC) (649/2012/EU)	
Not listed.		
Seveso Directive		
Date of issue/Date of revision	: 1-11-2022	Version : 1.01

	11 11 2022	
Date of previous issue	: 1-10-2022	16/19



SECTION 15: Regul	atory information
This product is controlled u	inder the Seveso Directive.
Danger criteria	
Category	
P5c	
National regulations	
Industrial use	: The information contained in this safety data sheet does not constitute the user's own assessment of workplace risks, as required by other health and safety legislation. The provisions of the national health and safety at work regulations apply to the use of this product at work.
VOC content	: VOC (w/w): 35.8%
International regulations	
	ntion List Schedules I, II & III Chemicals
Not listed.	
Montreal Protocol Not listed.	
Stockholm Convention on Not listed.	Persistent Organic Pollutants
Rotterdam Convention on Not listed.	Prior Informed Consent (PIC)
UNECE Aarhus Protocol o Not listed.	n POPs and Heavy Metals
Inventory list	
Europe	: Not determined.
15.2 Chemical Safety Assessment	: No Chemical Safety Assessment has been carried out.
SECTION 16: Other	information
Indicates information that	has changed from previously issued version.
Abbreviations and acronyms	 ATE = Acute Toxicity Estimate CLP = Classification, Labelling and Packaging Regulation [Regulation (EC) No. 1272/2008] DMEL = Derived Minimal Effect Level DNEL = Derived No Effect Level EUH statement = CLP-specific Hazard statement N/A = Not available PBT = Persistent, Bioaccumulative and Toxic PNEC = Predicted No Effect Concentration RRN = REACH Registration Number SGG = Segregation Group

vPvB = Very Persistent and Very Bioaccumulative

Procedure used to derive the classification according to Regulation (EC) No. 1272/2008 [CLP/GHS]

Classification	Justification
Flam. Liq. 3, H226	On basis of test data
Skin Irrit. 2, H315	Calculation method
Eye Irrit. 2, H319	Calculation method
STOT SE 3, H336	Calculation method
STOT RE 2, H373	Calculation method

Full text of abbreviated H statements

Date of issue/Date of revision	: 1-11-2022	Version : 1.01	
Date of previous issue	: 1-10-2022	17/19	AkzoNobel

SECTION 16: Other	r information
⊮ 225	Highly flammable liquid and vapor.
H226	Flammable liquid and vapor.
H304	May be fatal if swallowed and enters airways.
H312	Harmful in contact with skin.
H315	Causes skin irritation.
H317	May cause an allergic skin reaction.
H319	Causes serious eye irritation.
H332	Harmful if inhaled.
H335	May cause respiratory irritation.
H336	May cause drowsiness or dizziness.
H373	May cause damage to organs through prolonged or repeated
	exposure.
H412	Harmful to aquatic life with long lasting effects.
EUH066	Repeated exposure may cause skin dryness or cracking.
Full text of classifications	[CLP/GHS]
Acute Tox. 4	ACUTE TOXICITY - Category 4
Aquatic Chronic 3	AQUATIC HAZARD (LONG-TERM) - Category 3
Asp. Tox. 1	ASPIRATION HAZARD - Category 1
Eye Irrit. 2	SERIOUS EYE DAMAGE/ EYE IRRITATION - Category 2
Flam. Liq. 2	FLAMMABLE LIQUIDS - Category 2
Flam. Liq. 3	FLAMMABLE LIQUIDS - Category 3
Skin Irrit. 2	SKIN CORROSION/IRRITATION - Category 2
Skin Sens. 1	SKIN SENSITIZATION - Category 1
STOT RE 2	SPECIFIC TARGET ORGAN TOXICITY (REPEATED
	EXPOSURE) - Category 2
STOT SE 3	SPECIFIC TARGET ORGAN TOXICITY (SINGLE EXPOSURE)
	Category 3
Date of printing	: 1 November 2022
Date of issue/ Date of revision	: 1 November 2022
Date of previous issue	: 1 October 2022
Version	: 1.01
Unique ID	:
Notice to reader	

Notice to reader

FOR PROFESSIONAL USE ONLY

IMPORTANT NOTE The information in this data sheet is not intended to be exhaustive and is based on the present state of our knowledge and on current laws: any person using the product for any purpose other than that specifically recommended in the technical data sheet without first obtaining written confirmation from us as to the suitability of the product for the intended purpose does so at his own risk. It is always the responsibility of the user to take all necessary steps to fulfill the demands set out in the local rules and legislation. Always read the Material Data Sheet and the Technical Data Sheet for this product if available. All advice we give or any statement made about the product by us (whether in this data sheet or otherwise) is correct to the best of our knowledge but we have no control over the quality or the condition of the substrate or the many factors affecting the use and application of the product. Therefore, unless we specifically agree in writing otherwise, we do not accept any liability whatsoever for the performance of the product or for any loss or damage arising out of the use of the product. All products supplied and technical advice given are subject to our standard terms and conditions of sale. You should request a copy of this document and review it carefully. The information contained in this data sheet is subject to modification from time to time in the light of experience and our policy of continuous development. It is the user's responsibility to verify that this data sheet is current prior to using the product.

Brand names mentioned in this data sheet are trademarks of or are licensed to Akzo Nobel.



Date of issue/Date of revision
Date of previous issue

